Jon started his scientific career in academia as a member of scientific staff in the Biochemistry Department, Imperial College and then moved to the Medical Research Council Toxicology Unit as a Senior Scientific Officer working on mechanisms of carcinogenesis. Jon joined Cambridge Antibody Technology, (CAT), in 1992 as a Senior Scientist, working on multiple drug discovery projects. After a few years, Jon then joined a new team establishing the process development group before eventually moving across into operational management. CAT merged with Medimmune (a wholly owned subsidiary of Astra Zeneca) in 2006 where Jon latterly held the post of VP, Site General Manager a position he held for some years. At Medimmune Jon led the multidisciplinary site operations of the Cambridge R & D facilities, a site of some 800 staff. In 2021 Jon joined Iontas, a world leading contract research organisation in the antibody engineering field, as Chief Operating Officer.
Jon is the current Chair of the Board of One Nucleus and holds several other NED appointments including, Stevenage Bioscience Catalyst. Jon has an MPhil in molecular biology/cellular pathology, is a Chartered Biologist and Fellow of the Royal Society of Biology. Jon is also a Fellow of the Royal Society of Arts and Manufacturing and the Institute of Directors.